Guggenheim: Valeant to Surge 70%, Price Target $19
Post# of 193
Posted On: 12/17/2015 3:02:04 PM
Guggenheim: Valeant to Surge 70%, Price Target $195
Today, Guggenheim reiterated a "Buy" rating for Valeant Pharmaceuticals (NYSE) with a price target of US $195, which represents +70% upside.
Current VRX share price on NYSE is $112.
The price target of US $195 VRX (NYSE) translates into a price target of CDN $272 for VRX listed on Toronto Stock Exchange.
http://www.marketbeat.com/stocks/NYSE/VRX/
Today, Guggenheim reiterated a "Buy" rating for Valeant Pharmaceuticals (NYSE) with a price target of US $195, which represents +70% upside.
Current VRX share price on NYSE is $112.
The price target of US $195 VRX (NYSE) translates into a price target of CDN $272 for VRX listed on Toronto Stock Exchange.
http://www.marketbeat.com/stocks/NYSE/VRX/
(0)
(0)Bausch Health Companies Inc. (BHC) Stock Research Links
Scroll down for more posts ▼